
Immunomic Therapeutics Doses First Patient in Phase 1 Trial of Allergy Vaccine Candidate ITI-9001
HLB Subsidiary Immunomic Therapeutics Announces First Patient Dosed in Phase 1 Trial of Allergy Vaccine Candidate ITI-9001 Immunomic Therapeutics Inc., a clinical-stage biotechnology company and a subsidiary of HLB, announced that the first participant has been dosed in the Phase…











